Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine platforms aiming to control and eliminate ZIKV-induced disease. Analysis of key immunization and pathogenesis studies in multiple animal models, including during pregnancy, has begun to define immune correlates of protection. Nonetheless, the deployment of ZIKV vaccines, along with the confirmation of their safety and efficacy, still has major challenges, one of which is related to the waning of the epidemic. In this review, we discuss the measures that enabled rapid progress and highlight the path forward for successful deployment of ZIKV vaccines.

中文翻译：

---

寨卡病毒疫苗的开发：面对新挑战的进展。

寨卡病毒（ZIKV）传播到美洲时已在全球范围内出现，并于2015年开始引起先天性畸形和小头畸形。学术界，政府，公共卫生基础设施和行业的快速反应使套件的开发和测试得以快速进行。旨在控制和消除ZIKV引起的疾病的疫苗平台。在包括怀孕期间在内的多种动物模型中进行的关键免疫和发病机理研究的分析已开始确定保护的免疫相关性。尽管如此，部署ZIKV疫苗以及确认其安全性和有效性仍面临重大挑战，其中之一与流行病的消退有关。在这篇综述中，我们讨论了可实现快速进展的措施，并突出了成功部署ZIKV疫苗的道路。